Grail shares fall after large cancer blood test data yields mixed results
BUZZ-Grail shares fall after large cancer blood test data yields mixed results ** Shares of cancer test maker Grail GRAL.O fall 15.5% to $60.58 after detailed results from a large UK study of its Galleri multi-cancer blood test raised investor concerns
** Grail previously said at the American Society of Clinical Oncology meeting that the NHS-Galleri trial missed its primary goal of significantly reducing stage III and IV cancer diagnoses across 12 pre-specified cancer types
** The company highlighted signs of benefit, including fewer stage IV cancers and more early-stage diagnoses, but Guggenheim analysts questioned whether the data was strong enough to support broad use in average-risk patients
** Guggenheim said the ASCO presentation drew skepticism over whether Galleri may be better suited for high-risk groups
** The brokerage also noted concerns that many early-stage cancers detected were colorectal and lung cancers, which already have established screening options
** Including session's move, GRAL stock down 29.4% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM